Diabetic Macular Edema Market By Treatment Type (Anti VEGF Injections, Corticosteroids, Laser Treatment, Vitrectomy Surgery); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Diabetic Macular Edema Market Size and Why Is Revenue Shifting Toward Durable Retinal Therapy?

The Global Diabetic Macular Edema Market was valued at USD 4.75 billion in 2025 and is projected to reach USD 7.10 billion by 2032, expanding at a CAGR of 5.9% during 2026–2032, according to Strategic Market Research.

 

Diabetic macular edema (DME) is a diabetes-driven retinal disorder caused by vascular leakage and fluid accumulation in the macula, creating significant clinical need for vision-preserving therapies. Companies such as Regeneron Pharmaceuticals, Roche/Genentech, and Novartis compete through advanced retinal therapies including Eylea, Vabysmo, and Lucentis. With 589 million adults living with diabetes globally in 2024 and approximately 5.47% developing DME, the market opportunity is expanding, although commercial treatment eligibility depends on disease severity, diagnosis rates, and therapy adoption.

 

Intravitreal anti-VEGF agents remain the first-line option for most center-involved DME patients, with marketed therapies including Eylea (aflibercept), Eylea HD, Lucentis (ranibizumab), Beovu (brolucizumab), and Vabysmo (faricimab), while bevacizumab continues as a widely used off-label alternative. Companies are increasingly competing on durability and reduced injection burden, supported by innovations such as Susvimo’s 24-week refill system, aflibercept biosimilars, and pipeline programs including Kodiak’s KSI-501 and 4D Molecular Therapeutics’ 4D-150.

 

The diabetic macular edema treatment market is supported by a large global diabetic population and a significant vision-threatening disease burden. Approximately 21 million people worldwide are affected by DME, representing nearly 6.81% of individuals with diabetes, with higher prevalence among Type 1 diabetes patients. In the United States, around 746,000 adults aged 40 years and above have DME, while prevalence varies across demographics.

 

SMR Analyst Thesis

Analyst Priority	SMR Thesis
Revenue Mix	Anti-VEGF is unlikely to lose its central role through 2032, but the revenue mix is shifting away from standard-dose branded injections toward premium durability and lower-cost biosimilars.
Commercial Unit	The most important commercial unit is the persistently controlled eye-year, not the theoretical number of people with diabetes or the number of injections alone.
Pipeline Disruption	The main disruptive pipeline risks to repeated intravitreal dosing are sustained delivery, multi-pathway biologics and intravitreal gene therapy; the May 2026 failure of topical OCS-01 reduced the probability of near-term eye-drop disruption.

 

Diabetic Macular Edema Market Snapshot 2025: Treatment Mix and Regional Revenue Structure

Treatment Type

• Anti-VEGF Injections – 74.0% share in 2025 and 6.5% CAGR; the largest revenue pool because first-line clinical use is now being reinforced by high-dose, dual-pathway and biosimilar competition.

• Corticosteroids – 13.0% share and 5.2% CAGR; a second-line and treatment-burden segment centered on persistent DME, steroid-responsive eyes and patients unsuitable for frequent anti-VEGF treatment.

• Laser Treatment – 8.0% share and 2.4% CAGR; a residual/selective revenue pool used mainly in non-center-involving or adjunctive treatment rather than a source of major incremental market growth.

• Vitrectomy Surgery – 5.0% share and 3.5% CAGR; a specialist procedural segment linked to refractory disease with vitreomacular traction, epiretinal membrane or other mechanical contributors.

 

Geography

• North America – 43.0% share and 5.6% CAGR; the leading revenue region because premium retinal products, Medicare Part B economics, specialist capacity and early commercialization of biosimilars coexist in the same market.

• Europe – 26.0% share and 4.9% CAGR; increasingly shaped by procurement economics, biosimilar-first pathways and pressure to lower the cost per controlled eye while preserving clinical outcomes.

• Asia-Pacific – 22.0% share and 7.6% CAGR; the fastest-growing region, with the largest long-term treated-eye volume opportunity but substantial variation in screening, reimbursement and injection intensity.

• Latin America – 5.0% share and 6.2% CAGR; growth is more dependent on diagnosis, retina referral and affordable anti-VEGF access than on immediate premium-product penetration.

• Middle East & Africa – 4.0% share and 5.5% CAGR; a large underlying diabetes burden but lower conversion into treated DME revenue because retinal imaging, specialist access and reimbursement remain uneven.

 

Anti-VEGF Dominance Defines the Diabetic Macular Edema Treatment Economy

Anti-VEGF injections accounted for 74.0% of the market, representing USD 3.515 billion in 2025, and are projected to expand at a CAGR of 6.5% during 2026–2032. Their leadership reflects both guideline position and recurring administration. ADA 2026 identifies anti-VEGF as first-line treatment for most center-involved DME with impaired visual acuity, while U.S. Vestrum Health data showed anti-VEGF monotherapy increasing from 43.5% of treated eyes in 2015 to 61.8% in 2020. Regeneron is extending the aflibercept franchise through Eylea HD, Roche competes with dual VEGF-A/Ang-2 inhibition through Vabysmo and sustained ranibizumab delivery through Susvimo, and Biocon has introduced an interchangeable aflibercept biosimilar into U.S. commercialization. These products compete less on whether VEGF inhibition works and more on dosing duration, access and total treatment cost.

Corticosteroids accounted for 13.0% of the market, representing USD 617.5 million in 2025, and are expected to expand at a CAGR of 5.2%. Their role is concentrated in persistent or inadequately controlled DME and in patients for whom repeated anti-VEGF injections are unsuitable. NICE supports intravitreal steroid implants in selected patients after suboptimal anti-VEGF response or when frequent injections are difficult to sustain. Long-acting fluocinolone acetonide, now represented in the U.S. retina portfolio of ANI Pharmaceuticals through ILUVIEN, provides an extended-duration option, but cataract progression and intraocular-pressure elevation limit broad first-line use.

Laser treatment held an 8.0% share, equal to USD 380.0 million in 2025, and is forecast to grow at a CAGR of 2.4%. The segment has become a selective rather than central DME revenue pool. Vestrum data showed focal laser monotherapy declining from 9.7% of treated eyes in 2015 to 3.0% in 2020 as intravitreal treatment became standard. Laser still has a role in selected non-center-involving edema and as adjunctive therapy, but its slow CAGR reflects structural displacement by pharmacologic retinal control rather than lack of clinical usefulness.

Vitrectomy surgery represented 5.0% of the market, or USD 237.5 million in 2025, and is projected to expand at a CAGR of 3.5%. The procedure is concentrated in refractory DME associated with vitreomacular traction, epiretinal membrane or other mechanical contributors. It therefore follows complex-case volume rather than the broader DME population and should be viewed as a specialist procedural niche rather than a competing first-line treatment pathway.

 

Regional Diabetic Macular Edema Economics: Premium Mix, Procurement Pressure and Volume Expansion

North America accounted for 43.0% of the market, approximately USD 2.04 billion in 2025, and is projected to expand at a CAGR of 5.6%. The region combines a large diagnosed diabetes population, retina-specialist capacity, OCT-based monitoring and reimbursement for physician-administered biologics. CDC estimated 40.1 million people in the United States had diagnosed or undiagnosed diabetes in 2023, including 29.1 million with diagnosed disease. The commercial mix is unusually broad: premium Eylea HD, Vabysmo and Susvimo compete alongside off-label bevacizumab and newly commercialized aflibercept biosimilars. Medicare Part B economics make net drug cost and provider reimbursement particularly influential in share migration.

Europe held 26.0% of the market, approximately USD 1.24 billion in 2025, and is forecast to grow at a CAGR of 4.9%. The region's defining feature is not weaker clinical adoption but stronger control of medicine value through national reimbursement and procurement. NHS England reported almost 4.6 million diagnosed diabetes cases in England in 2023/24 and cites evidence suggesting about 7% may have DMO. Its 2026 pathway uses biosimilar-first treatment economics while preserving access to longer-acting branded options when clinically appropriate. Europe can therefore expand treated volume while average revenue per injection comes under greater procurement pressure.

Asia-Pacific represented 22.0% of the market, approximately USD 1.05 billion in 2025, and is projected to register the fastest CAGR of 7.6%. The region combines a large diabetes population with wide variation in screening, reimbursement and retinal-specialist density. Japan demonstrates the direction of pharmacologic adoption: claims data showed DME anti-VEGF injection rates rising substantially between 2014 and 2020, yet patients still averaged only about 3.5 injections in the first treatment year in 2020. The regional opportunity is therefore not only more patients but better conversion from diagnosis into persistent retinal treatment.

Latin America accounted for 5.0% of the market, approximately USD 0.24 billion in 2025, and is projected to grow at a CAGR of 6.2%. Near-term expansion is more likely to come from retinal referral, OCT access and affordable anti-VEGF availability than from immediate conversion to premium sustained-delivery platforms. Aflibercept and ranibizumab biosimilar availability could therefore have disproportionate importance in broadening the treated-eye pool.

Middle East & Africa held 4.0% of the market, approximately USD 0.19 billion in 2025, and is expected to expand at a CAGR of 5.5%. The underlying diabetes burden is substantial, but treatment monetization is constrained by uneven retinal screening, specialist access, injection capacity and payer coverage. Lower-cost anti-VEGF therapy is likely to be the most scalable commercial entry point, while premium high-duration products remain concentrated in higher-resource centers.

 

Competitive Repositioning Across the Diabetic Macular Edema Market

Regeneron Pharmaceuticals, Inc.
Develops and commercializes Eylea (aflibercept), a leading anti-VEGF therapy widely used for DME treatment. The company continues to expand its retinal disease portfolio through next-generation therapies and longer-duration treatment approaches.

Genentech (Roche Group)
Provides major retinal biologics including Lucentis (ranibizumab) and Vabysmo (faricimab). The company focuses on advancing retinal care through anti-VEGF and dual-pathway therapies designed to improve treatment outcomes and reduce injection burden.

AbbVie Inc.
Offers Ozurdex (dexamethasone intravitreal implant), a sustained-release corticosteroid therapy used for DME patients requiring anti-inflammatory treatment. AbbVie strengthens its ophthalmology presence through advanced drug delivery technologies.

Alimera Sciences, Inc.
Specializes in long-acting ophthalmic treatments and markets Iluvien (fluocinolone acetonide implant) for chronic DME management, focusing on reducing treatment frequency and improving long-term disease control.

Clearside Biomedical, Inc.
Develops innovative ocular drug delivery platforms targeting the back of the eye. Its suprachoroidal delivery technology aims to improve precision and expand treatment options for retinal disorders, including macular edema.

Novartis AG
A major global ophthalmology player that commercializes Beovu (brolucizumab) and invests in advanced retinal disease therapies. The company focuses on improving efficacy, durability, and patient outcomes in retinal vascular conditions.

Bayer AG
Markets Eylea (aflibercept) in several international markets and maintains a strong ophthalmology pipeline through investments in retinal therapeutics, gene therapy, and innovative treatment platforms.

F. Hoffmann-La Roche Ltd
Drives retinal innovation through biologics such as Vabysmo and research programs focused on advanced mechanisms, longer treatment intervals, and improved management of retinal vascular diseases.

Formycon AG
Develops biosimilar candidates for established biologic therapies, supporting broader accessibility and cost-efficient alternatives within the ophthalmology and retinal disease treatment landscape.

Santen Pharmaceutical Co., Ltd.
Focuses exclusively on ophthalmology and develops specialized eye-care therapies for retinal and ocular surface disorders across Japan, Asia-Pacific, and global markets.

Chugai Pharmaceutical Co., Ltd.
A Roche Group company involved in antibody-based drug discovery and advanced biologics research, including therapies targeting ophthalmic disease pathways.

Otsuka Pharmaceutical Co., Ltd.
Participates in ophthalmology innovation through partnerships and development programs focused on sustained drug delivery systems and retinal disease treatment solutions.

Biocon Limited
Expands its global presence in complex biologics and biosimilars, supporting wider availability of advanced ophthalmic treatments through cost-effective therapeutic alternatives.

Samsung Bioepis Co., Ltd.
Develops biosimilar versions of major biologic medicines, contributing to increased affordability and accessibility of retinal therapies used in diseases such as DME.

 

Analyst Commentary: The Next Breakthroughs Reshaping Diabetic Macular Edema Care

The most important breakthrough in the diabetic macular edema market is likely to come from therapies that reduce dependence on repeated intravitreal injections rather than simply improve anti-VEGF efficacy incrementally. Extended-duration anti-VEGF products such as Eylea HD and Vabysmo are already moving treatment toward longer intervals, but the larger structural opportunity lies in sustained retinal therapy. Among pipeline technologies, intravitreal gene therapy currently has the greatest potential to change the treatment model, because it could convert DME from a chronic injection-based disease into one managed with a single or very infrequent administration. This would directly address one of the market's largest problems: real-world patients frequently receive fewer injections than recommended and often discontinue therapy because of visit burden.

4D Molecular Therapeutics' 4D-150 is currently the most important gene-therapy asset to watch. The therapy is designed to enable retinal cells to continuously produce anti-VEGF activity after one intravitreal administration, targeting VEGF-A, VEGF-B, VEGF-C and placental growth factor pathways. FDA RMAT designation and progression toward Phase III development strengthen its strategic relevance. If late-stage trials confirm multi-year efficacy with an acceptable ocular safety profile, 4D-150 could become the first technology capable of materially disrupting the repeated-injection economics of DME. The commercial impact would extend beyond product substitution: manufacturers, retina specialists and payers would need to shift from evaluating annual injection cost toward multi-year value per controlled eye. However, long-term inflammation, durability, retreatment requirements and pricing will determine whether gene therapy becomes broadly used or remains concentrated in selected patients.

The second major breakthrough candidate is Kodiak Sciences' KSI-501, which may be commercially important for a different reason. KSI-501 combines VEGF inhibition with IL-6 blockade, targeting both vascular leakage and inflammatory biology. Its Phase III ALTO trial is particularly important because it is designed to test superiority against aflibercept rather than simply demonstrate comparable performance. A successful result could establish VEGF plus inflammatory-pathway inhibition as a new therapeutic class, particularly for patients who respond incompletely to VEGF-only therapy. This could challenge the current assumption that DME innovation is primarily a competition over longer dosing intervals. If KSI-501 fails to demonstrate meaningful superiority, however, the market is likely to remain centered on increasingly durable VEGF-based products.

In the nearer term, Eylea HD and Vabysmo are more likely to generate the largest commercial gains than gene therapy, because they reduce treatment burden without forcing retina specialists to adopt a fundamentally different treatment pathway. Susvimo also validates sustained ocular delivery, but implantation requirements and endophthalmitis risk are likely to keep it more selective. At the opposite end of the market, aflibercept and ranibizumab biosimilars will increasingly pressure standard-dose branded anti-VEGF products. This is likely to create a two-tier market: lower-cost biosimilars for price-sensitive treatment and premium durable therapies for patients where fewer visits justify higher acquisition costs.

 

Diabetic Macular Edema Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.75 Billion
Revenue Forecast in 2032	USD 7.10 Billion
Overall Growth Rate	CAGR of 5.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Geography
By Treatment Type	Anti-VEGF Injections, Corticosteroids, Laser Treatment, Vitrectomy Surgery
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Australia, Japan, South Korea, India, China, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Large global diabetes population, increasing diagnosis of vision-threatening DME, continued anti-VEGF use, longer-duration retinal therapies, sustained-delivery platforms, biosimilar commercialization and intravitreal gene-therapy development
Customization Option	Available upon request